GeoVax Labs, Inc.

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies targeting infectious diseases and solid tumor cancers. The company employs proprietary vaccine platforms to create preventive and therapeutic candidates across multiple disease areas. Its preventive vaccine pipeline includes programs against COVID-19, HIV, Zika virus, malaria, and hemorrhagic fever viruses including Ebola, Sudan, Marburg, and Lassa. On the therapeutic side, the company is developing vaccines for HIV, chronic Hepatitis B, and solid tumors, as well as Gedeptin, a novel immunotherapy for advanced head and neck squamous cell carcinoma.

The company's most advanced candidate, GEO-CM04S1, is in Phase 2 clinical trials for COVID-19 prevention. GEO-CM02, a pan-coronavirus vaccine, and GEO-MVA-MUC1, a solid tumor vaccine candidate, represent additional pipeline assets. Earlier-stage programs in preclinical development include vaccine candidates for Zika, Ebola variants, Marburg, Mpox, and smallpox.

GeoVax Labs operates with a small team of 17 full-time employees and is headquartered in Smyrna, Georgia. The company has established collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, and the Burnet Institute, reflecting its focus on infectious disease and cancer immunology research.